• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Hydroquinolines

Recent Advances in the Study of (5,6,7,8-tetrahydroquinolin-3-yl)methanamine (CAS: 103041-34-5) in Chemical Biology and Pharmaceutical Research

The compound (5,6,7,8-tetrahydroquinolin-3-yl)methanamine (CAS: 103041-34-5) has garnered significant attention in recent chemical biology and pharmaceutical research due to its versatile pharmacological properties and potential therapeutic applications. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and emerging applications in drug discovery.

Recent studies have highlighted the role of (5,6,7,8-tetrahydroquinolin-3-yl)methanamine as a key intermediate in the synthesis of novel bioactive molecules. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of selective serotonin receptor modulators, which show promise in treating neurological disorders such as depression and anxiety. The compound's unique structural features, including its tetrahydroquinoline scaffold, contribute to its high binding affinity and selectivity for target proteins.

In addition to its neurological applications, (5,6,7,8-tetrahydroquinolin-3-yl)methanamine has been investigated for its potential in oncology. Research published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that derivatives of this compound exhibit potent inhibitory effects against specific kinase targets involved in cancer cell proliferation. These findings suggest its potential as a lead compound for the development of targeted cancer therapies.

The synthetic pathways for (5,6,7,8-tetrahydroquinolin-3-yl)methanamine have also seen significant optimization in recent years. A 2024 study in Organic Process Research & Development reported a novel, high-yield synthesis method that improves both the efficiency and scalability of production. This advancement is particularly important for facilitating further pharmacological studies and potential commercialization.

Pharmacokinetic studies of (5,6,7,8-tetrahydroquinolin-3-yl)methanamine derivatives have shown favorable absorption and distribution profiles, with good blood-brain barrier penetration in animal models. These properties, combined with its relatively low toxicity profile, make it an attractive candidate for further drug development. However, researchers note that additional studies are needed to fully understand its metabolic pathways and potential drug-drug interactions.

Looking forward, the versatility of (5,6,7,8-tetrahydroquinolin-3-yl)methanamine suggests it will continue to be an important building block in medicinal chemistry. Current research directions include exploring its applications in inflammation modulation and infectious disease treatment, as well as further optimization of its pharmacological properties through structural modifications. The compound's CAS number (103041-34-5) serves as a crucial identifier for tracking these developments in chemical databases and patent literature.

• 10500-57-9(5,6,7,8-Tetrahydroquinoline)
• 28712-62-1(3-methyl-5,6,7,8-tetrahydroquinoline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)